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Abstract
Background: There is a growing need for an evidence-based approach to home support for people with dementia
and their carers following diagnosis but research on the effectiveness and cost-effectiveness of different approaches
is sparse. The Dementia Early Stage Cognitive Aids New Trial (DESCANT) will evaluate the clinical and cost-
effectiveness of a range of memory aids, training and support to people with mild to moderate dementia
and their carers at home and compares that intervention with treatment as usual.
Methods/design: This is a multi-site, pragmatic randomised trial preceded by a feasibility study and internal pilot. We
aim to allocate at random 360 pairs comprising a person with mild to moderate dementia and an identified carer
between the DESCANT intervention and treatment as usual. We assess participants at baseline, 13 and 26 weeks. The
primary outcome measure is the Bristol Activities of Daily Living Scale; other participant outcomes include cognition,
quality of life, activities of daily living and social networking; carer outcomes include quality of life, sense
of competence and mental health. To enhance this quantitative evaluation we are conducting a qualitative
component and a process evaluation to assess the implementation process and identify contextual factors
associated with variation.
Discussion: The DESCANT intervention reflects current policy to enhance the capabilities of people with
dementia after diagnosis and their carers. If it is clinically and cost-effective, its modest nature and cost will
enhance the likelihood of it being incorporated into mainstream practice.
Trial registration: Current Controlled Trials, ISRCTN12591717. Registered on 29 July 2016.
Protocol number: 31288: North West - Haydock Research Ethics Committee, 20/06/2016, ref.: 16/NW/0389.
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Background
Worldwide there were about 47 million people living with
dementia in 2015; since there is no cure the costs associ-
ated with the condition will increase [1]. In England there
is considerable interest in achieving early diagnosis and
treatment of dementia through memory services, and pro-
viding a spectrum of care including interventions and sup-
port after diagnosis [2–4]. Diagnosis can help people with
dementia and their carers to receive the treatment, care
and support (pharmacological, psychosocial, social and
emotional) to enable them to manage this condition.
Rigorous research is required to inform the choice of
treatment options [5]. However robust evaluation of the
use of common memory aids, like calendars, clocks, white-
boards with electric timers and “post-it” note dispensers, by
those diagnosed with early dementia is lacking despite be-
ing widely recommended [6, 7] . A Cochrane review [8]
identified several studies that reported the utility of
memory aids or associated memory training, but they were
small scale, highlighting the need for a larger study [9–11].
This trial aims to design, implement and evaluate an
intervention to support people with early-stage dementia
and their carers in the use of memory aids at home. It is
one of nine distinct, but linked, projects within a research
programme designed to discern different models of sup-
port in England and evaluate cost-effectiveness in provid-
ing care for people with dementia and their carers at
home; the Personal Social Services Research Unit (PSSRU)
at the University of Manchester is leading this trial.
Figure 1 shows a Consolidated Standards of Reporting
Trials (CONSORT) flowchart of the trial.
Methods/design
Governance arrangements
The Programme Steering Committee (PSC) oversees the
programme of which this trial is part. It comprises
Fig. 1 DESCANT trial flowchart
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representatives of patients and public, old age psychiatry,
psychology, health services research and biostatistics,
and works to an agreed Charter. It also acts as the inde-
pendent Trial Steering Group.
This trial has been adopted by the Swansea Trials Unit
(STU) and will be conducted according to its standard
operating procedures. The Trial Management Group
comprises PSSRU staff at the University of Manchester,
and it monitors compliance and reports to NHS Trusts,
oversees and resolves operational issues in partnership
with colleagues at STU, and reports to the Data Moni-
toring and Ethics Committee (DMEC) and the funder,
the National Institute of Health Research (NIHR). The
DMEC meets at least annually and reports to the PSC;
the chair is a geriatrician with a particular interest in de-
mentia, and their charter reflects established practice
[12]. Only the DMEC have access through the Trial Data
Manager to unblinded data before the trial ends; it will
unblind the DESCANT analysis team only after approv-
ing the blinded primary analysis.
The Public, Patient and Carer Reference Group
(PPCRG) comprises a regular meeting of 6 members
resident in North West England and a Lay Advisory
Panel of 20 members across the country, established
through Together in Dementia Everyday (TIDE).
Design
This is a multi-site, pragmatic randomised trial to evaluate
the effectiveness and cost-effectiveness of memory aids
delivered by Dementia Support Practitioners (DSPs) to
people with early-stage dementia relative to treatment as
usual (TAU). Pairs of people with mild to moderate de-
mentia and an identified carer will be recruited and allo-
cated at random between the comparator group receiving
TAU plus dementia guide [13] and the intervention group
receiving TAU plus the DESCANT intervention. The pri-
mary outcome measure is the Bristol Activities of Daily
Living Scale (BADLS) [14], measured at 13 and 26 weeks
(primary end point) after baseline.
To ensure intervention and methods work in practice, a
feasibility study and internal pilot was conducted with 40
participants, recruited from two settings in equal num-
bers. The Acceptance Checklist for Clinical Effectiveness
Pilot Trials (ACCEPT) criteria [15] was adapted to assess
whether the intervention and the trial protocol work in
practice, and the DMEC had accepted these criteria. The
only adjustments suggested by the pilot was to reduce the
length of follow up from 12 to 6 months in the main study
to enable the recruitment targets to be met and reflect the
realistic goal of improving BADLS scores over 6 months.
Therefore, the pilot data will be included, adjusted to re-
flect this change in the main analysis. This modification,
approved by the University of Manchester as Sponsor, was
communicated to the National Research Ethics Service
who approved the original protocol (reference 15/NW/
0822), sites and participants.
Intervention
The manualised intervention adds specialist equipment
and advice by trained DSPs to TAU. It provides up to 6
hours contact with a DSP for the person with dementia
and the identified carer (jointly referred to as partici-
pants). DSPs design and deliver a package of memory
aids up to a maximum of £150 for the person with de-
mentia to use at home. The package for each depends
on their needs, preferences and existing use of memory
aids. DSPs also advise on improving everyday memory
skills and on using these aids to reduce memory lapses.
The follow-up sessions address queries from participants
and record whether aids are appropriate to the identified
goals and needs and used accordingly. Further details
about the implementation of the intervention are pro-
vided in Fig. 2.
Treatment as usual
TAU comprises help from memory clinic staff, post diag-
nostic counselling and advice, and specialist follow up as
appropriate. Participants in the comparator group also
receive a general guide to dementia for patients and
carers [13].
Setting
The study runs in three National Health Service (NHS)
Trusts in England, and more may follow. To be eligible
participating Trusts must provide a memory service, a
health-based resource providing early diagnosis and sup-
port for people with dementia and their carers. They must
also identify a local Principal Investigator (PI), obtain sup-
port from their local Research and Development depart-
ment and Clinical Research Network (CRN) to complete
the research activities described in this protocol, and em-
ploy appropriately experienced persons as DSPs.
Participants will be recruited primarily from memory
services. “Join Dementia Research,” an on-line self-regis-
tration service enabling volunteers with memory prob-
lems or dementia and their carers to register their
interest in taking part in research, will also be used as a
recruitment tool.
Participants
Inclusion criteria
Index people with dementia must be aged 50 years or
more; cared for by a trial memory clinic or equivalent;
within one year of their first attendance at that clinic for
dementia; physically able to engage with the intervention
(as judged from clinical records); clinically able to do so,
as judged by a responsible clinician and have dementia of
mild to moderate severity. At baseline, they must live in
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their own home or share a home with a relative. They
must have an identified carer, defined as the primary per-
son who feels responsible for and supports them. This
could be a family member, a close friend or a neighbour.
Recruitment
Sites
Sites will be recruited via professional and research net-
works, including the UK NIHR Clinical Research Net-
work (CRN). Participating Trusts will identify memory
clinics for inclusion in the study. Each site will confirm
their capacity to undertake the trial by completing the
Health Research Authority Statement of Activities as a
formal agreement with the Sponsor.
People with dementia and their carers
Clinical staff in participating Trusts are briefed about
the trial and provided with participant information
sheets (PISs) for potential participants. They will
complete a screening schedule to check eligibility, give
the PIS to participants, and seek oral consent to refer
them to the DESCANT team. Recruitment, documents
and processes were designed following guidance from
the PPCRG on language and format, to ensure that those
with cognitive impairment are fully informed and en-
gaged in the decision to take part.
Consent process
Clinical staff within agencies will introduce the study to
participants, provide them with PISs and obtain their
consent to contact by a member of the research team.
Before conducting the interview, researchers explain the
study to participants and obtain their formal consent.
Guided by the Mental Capacity Act 2005 [16], it is
judged that people with mild to moderate dementia
approached in this way have capacity to provide in-
formed consent, given sufficient time to decide.
Participants may withdraw from the trial at any time
for any reason. If they withdraw, a reason will be re-
corded unless they choose not to provide one. PIs may
also withdraw people with dementia from the trial if they
feel it is no longer in their best interest to continue. Un-
less participants request otherwise, data collected before
withdrawal will be retained for analysis. Each site main-
tains a log of people who satisfy the inclusion criteria
but are not recruited, including demographic details and
reasons for not consenting to participate if given.
Outcome measures
The schedule of outcome measures and assessment
points are provided in Fig. 3.
Primary outcome measure
Bristol Activities of Daily Living Scale This assesses
the independence of the person with dementia in activ-
ities of daily living [14]. As they may not always be aware
of their deficits, carers assess these. The measure cap-
tures basic and instrumental abilities including dressing,
bathing, food preparation and use of the telephone. It is
valid and reliable and responsive to change over time
Fig. 2 DESCANT intervention. Source: [62]
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[17]. Therefore, it is appropriate to evaluate a practical
intervention designed to extend a person’s competence
in daily living.
Secondary outcome measures for persons with dementia
Cognition (two measures) The Standardised Mini-
Mental State Examination (S-MMSE) is a brief widely
used self-completed test of cognitive function with good
validity and reliability, which measures the severity of
cognitive symptoms of dementia [18]. The Clinical De-
mentia Rating (CDR) is an interviewer-completed scale
to indicate level of impairment in six domains [19].
Quality of life (three measures) Investigating Choice
Experiments for the Preferences of Older People Cap-
ability measure for Older people (ICECAP-O) measures
quality of life in older people across five domains [20].
The control, autonomy, self-realisation and pleasure
19-item measure (CASP-19), measures quality of life in
older people across another four domains [21, 22]. Both
these measures are self-completed by the person with
dementia. The Dementia Quality of Life scale (DEM-
QOL) measures five domains of quality of life in demen-
tia and has good validity and reliability [23]; either the
person with dementia completes this or the carer com-
pletes a proxy version.
Activities of daily living The Revised Interview for De-
terioration in Daily living activities in Dementia
(R-IDDD) enables carers to rate patients’ initiative and
performance of daily living activities [24, 25].
Social network (two measures) The Lubben Social
Network Scale - Revised (LSNS-R) is designed to meas-
ure social isolation in older adults through perceived
support from family and friends [26]. The Practitioner
Fig. 3 Schedule of enrolment, interventions and assessment points. BADLS: Bristol Activities of Daily Living Scale; CASP-19: Control, Autonomy,
Self-realisation and Pleasure 19-item measure of quality of life; CDRS: Clinical Dementia Rating Scale; DEMQOL: Dementia Quality of Life scale;
ICECAP-O: ICEpop (Investigating Choice Experiments for the Preferences of Older People) CAPability measure for Older people; LSNS-R: Lubben
Social Network Scale - Revised; PANT: Practitioner Assessment of Network Type; R-IDDD: Revised Interview for Deterioration in Daily living activites
in Dementia; S-MMSE: Standardised Mini-Mental State Examination; GHQ-12: General Health Questionnaire; SSCQ: Short Sense of Competence
Questionnaire; CSRI: Client Service Receipt Inventory; RUD: Resource Utilisation in Dementia. Completion by 1 = carer; 2 = person with dementia;
3 = interviewer; 4 = either person with dementia or carer. Intervention A = Comparator group; Intervention B = Intervention Group
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Assessment of Network Type (PANT) [27, 28] allocates
participants to one of five types of network reflecting
their contact with family, friends and neighbours. The
person with dementia completes both measures.
Secondary outcome measures for carers
Quality of life (two measures) Carers complete both
the ICECAP-O [20] and CASP-19 [21, 22] as sum-
marised above.
Sense of competence The Short Sense of Competence
Questionnaire (SSCQ) enables carers to assess their own
competence to cope with the person with dementia [29].
Mental health The self-completed General Health
Questionnaire (GHQ-12) will be used to identify minor
psychiatric morbidity in carers [30].
Economic measures
Resource use (two measures) The Client Service Re-
ceipt Inventory (CSRI) is a template used extensively in
studies of mental health and dementia to record details
of formal services received [31]. This is supplemented by
study-specific measures of participants’ use of equip-
ment, adaptations and ambulances (formal support). The
Resource Utilisation in Dementia questionnaire (RUD)
complements the CSRI by estimating the volume, dur-
ation and cost of support from formal and informal
carers. People with dementia and carers complete both
measures [32].
Health-related quality of life The Euroquol 5-dimen-
sion 5-level questionnaire (EQ-5D-5 L) provides a sim-
ple descriptive profile that generates a single utility value
for health status to assess quality of life [33, 34]. The
person with dementia and the carer completes this scale.
Other data collected
Socio-demographic information Interviewers collect
socio-demographic data from both the person with de-
mentia and the carer.
Study-specific measures Interviewers collect data on
comorbidities in the person with dementia, current use
of memory aids and current medication. They also assess
how confident they are about participants’ allocation to
the trial groups.
Serious adverse events In accordance with Good Clin-
ical Practice all data collectors are encouraged to report
deaths and adverse events that are life threatening, re-
quire or extend hospitalisation, result in disability or in-
capacity or are otherwise significant.
Procedure
Data collection
Interviewers, who are masked to the allocated group,
interview participants face to face at home at baseline
and 13 and 26 weeks after first interview. Data quality
will be promoted in two ways: interviewers undertake
online training (focussing on completing outcome mea-
sures) and sites check all documents to minimise miss-
ing data.
Random allocation
The Trial Manager (TM) coordinates recruitment from
all sites and forwards details to STU through their
email-based randomisation service. After baseline inter-
views, the unmasked Trial Data Manager (TDM) at STU
oversees stratification of people with dementia by Trust,
age, gender, whether living with a carer and time since
first attendance at memory clinic or equivalent. Alloca-
tion between intervention and comparator groups using
dynamic software randomises participants in real time,
thus preventing subversion while ensuring (stochastic)
balance between the two groups [35].
The person with dementia receives a letter specifying
their allocated group and reminding them what this en-
tails. Those in the comparator group receive a general
guide to dementia [13]. The intervention group receive
confirmation of arrangements for an initial visit by the
DSP after about 2 weeks.
Masking
Interviewers, statisticians, economists, PSC and DMEC
will be masked to participants’ allocations between the
two groups. However, masking participants and DSPs is
not possible. To minimise the risk of bias [36], several
precautions are taken:
1. The fieldwork manual for interviewers and support
staff at each site explains the case for masking and
its importance.
2. Site coordinators are asked to deny interviewers
access to allocations, for example in the recruitment
log.
3. All staff are asked to minimise participant-specific
discussion.
4. Deliberate disclosure of participants’ allocations is
limited to serious adverse events or safeguarding
issues.
5. All cases of unmasking - by participants, interviewers,
clinical or support staff or researchers - are recorded,
including the reason for unmasking.
6. Masked interviewers record after each interview to
which group they judge the pair belong and with
how much confidence.
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7. Statistical tests will be undertaken to determine
whether, and if so how, unmasking implicitly or
explicitly affects estimated parameters.
Data management
Personal information will be held securely in accordance
with data protection legislation. Screening forms com-
pleted by clinic staff and questionnaires completed by
interviewers will be transferred to the TM by encrypted
NHSmail. Unmasked researchers supervised by the
TDM based at STU enter data into MACRO4 electronic
data collection system provided by Elsevier (2017) [37]
in accordance with the study-specific handbook [38].
Participants’ trial numbers will be used to link their data
and ensure they remain anonymous. A full audit trial
will be maintained by recording all amendments to data
with the reason and the time of amendment. Thus, the
Sponsor may also inspect or audit the study at any time.
The STU will compile the final trial dataset in MACRO4
and transfer it to the PSSRU only when it is complete.
Sample size
An analysable sample of 360 (180 in each group) across
participating Trusts would yield 80% power to detect an
effect size (standardised mean difference) of 0.30 on
BADLS when using a two-sided significance level of 5%.
To allow for 25% attrition (estimated from previous
similar studies) between baseline and final interviews the
aim is to recruit 480 randomised pairs of people with
mild to moderate dementia and an identified carer.
Process evaluation
The Medical Research Council advocates process evalua-
tions within trials of complex interventions to assess im-
plementation and identify contextual factors associated
with variation in outcomes [39]. To replicate the DES-
CANT intervention will need understanding of how it
works in the intervention group. Figure 4 shows the
process evaluation framework comprising a mix of stan-
dardised [40–42] and study-specific measures. Data are
also collected from participants about appropriateness
and timeliness and from DSPs about barriers and facili-
tators to implementation and future roll-out.
Qualitative data collection
To enhance evaluation of its intervention, DESCANT
includes a qualitative component. Audio-recorded struc-
tured interviews of a sub-sample of participating pairs
will provide richer contextual and conversational data
about participants’ experiences and assessments of the
role of aids in combating memory loss. These data will
be collected unobtrusively at baseline interview [43].
Participants will be included from the intervention and
comparator groups to avoid unmasking of interviewers by
the research team and ensure potential bias from
audio-recording affects each group equally. The sample
size will be set according to practical criteria like available
resources and time and when data saturation is achieved
[44]. It is predicted that this will need a judgement sample
of at least 15 participants identified sequentially from the
baseline sample.
Statistical analysis
Analysis will follow a defined statistical analysis plan ap-
proved by the DMEC before data are accessed. Baseline
characteristics of participants will be presented. Con-
tinuous variables will be reported by means and standard
deviations and categorical variables by counts and per-
centages. Analyses by treatment allocated will estimate
the effect of the intervention on participants, using ana-
lysis of covariance to adjust for baseline differences in
demographic characteristics, comorbidities, time since
first attendance at memory clinic or equivalent and for
the interval until follow up. Primary analysis will focus
on BADLS scores at 26 weeks. Secondary analysis will
take account of the content of, and adherence to, the
intervention to explore the effect of compliance on
BADLS scores.
To explore whether people with dementia who have
particular characteristics are more likely to use specific
aids, logistic regression will be used. To identify which
participants are more likely to benefit from this inter-
vention, linear regression will be used to relate change
in BADLS scores at 26 weeks to similar covariates.
Whether the inevitable missing data cause bias will be
investigated. If predictors of missing data are identified
that are related to outcomes, multiple imputation to ad-
just for these biases will be used.
Economic evaluation
Cost-effectiveness analysis will be undertaken to evaluate
the full cost of this intervention and whether it yields
value for money. National unit costs for specific items of
service will be used to estimate the costs of services
used. Primary analysis will estimate quality-adjusted life
years (QALYs) from the EQ-5D-5 L using the value set
recommended by the National Institute for Health and
Care Excellence (NICE) at the time of the analysis [45].
Current value sets include the EQ-5D-5 L specific utility
weights [46] and the crosswalk algorithm to map the
EQ-5D-5 L survey to the EQ-5D-3 L value set [47].
QALYs gained between baseline and follow-up inter-
views (13 and 26 weeks) will be estimated as the number
of weeks multiplied by the utility of observed survival.
Covariates that affect costs or outcomes from relevant
published economic evaluations will be identified [48].
Adjusted costs and QALYs will be bootstrapped to esti-
mate pairs of net costs and QALYs. These will then be
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used to estimate the probability that the intervention
may be cost-effective. Net benefit will be estimated by
valuing net QALYs to reflect decision makers’ willing-
ness to pay (WTP) for one QALY. Recent decisions by
the NICE suggest that WTP is at most £20 k [49, 50].
Cost-effectiveness planes and cost-effectiveness accept-
ability curves (CEACs) will be plotted to summarize un-
certainty associated with incremental cost-effectiveness
ratios by the probability that the intervention in question
is cost-effective [51].
This economic model will be varied to explore uncer-
tainty arising from study design decisions by using
higher and lower sets of unit costs; an earlier estimate of
utility from the EQ-5D-5 L [47]; BADLS, the primary
outcome measure, or the DEM-QoL to measure health
benefit; different approaches to missing data (for ex-
ample by analysing only complete cases) and predicting
costs and QALYs over longer time horizons (for ex-
ample 5 and 10 years).
Process data analysis
This analysis will use the framework in Fig. 2. Again,
continuous variables will be reported by means and
standard deviations and categorical variables by counts.
Both standardised and study-specific measures will need
analysis of covariance to identify predictive factors.
Qualitative data analysis
Thematic and narrative analysis of interview transcripts
will be undertaken to elicit the experiences of people
with dementia and their carers. At least two researchers
will analyse each transcript. Once all issues have been
identified, an iterative process will be used to identify
the major themes and processes through conceptual ab-
straction. Achievement of data saturation will be in-
formed by a focus group of interviewers [52].
Discussion
This programme of work focusses on formal support at
home from health and social services to complement in-
formal support provided by family and friends. It includes:
supportive practical and emotional help; structured thera-
peutic interventions, such as counselling; and education,
including training in managing behaviour [53]. This trial
was designed to fill a knowledge gap identified by preced-
ing systematic review [54]. It also took account of another
recent study within the programme, which showed that
people with dementia prefer advice on memory aids to be
provided at home by a trained worker [55].
There is little evidence on the effectiveness and
cost-effectiveness of support for people with dementia and
their carers [56–58]. Nevertheless, English health and so-
cial care policy continues to emphasise the importance of
early diagnosis and support for people with dementia liv-
ing in their own homes [59, 60]. This assumes that this
will improve the quality of life of people with dementia. If
so this needs an evidence-based framework for a national
pathway with an affordable implementation plan to im-
prove the quality of post-diagnosis dementia care [60].
There are benefits to health and social care from knowing
what forms of home support enhance patients’ experience
Fig. 4 Process evaluation framework for intervention group
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and management of symptoms, over what is currently avail-
able. The trial will contribute to this evidence base if the
intervention is clinically effective and cost-effective. It is
hypothesised that by supporting the cognitive abilities of
people with early dementia, memory aids, and training and
support in their use, may improve their function, health
and well-being and that of their carers. This trial will there-
fore evaluate the effects on people with dementia and their
carers of this modest intervention, designed to be cheap,
realistic and scalable [61].
It is planned to present findings to professionals who
care for people with dementia; and to submit them for
publication in journals reporting research into assistive
technologies. These findings will also inform other stud-
ies within the programme, notably, economic modelling
of the effects of different home support packages and
the development of a toolkit for managers and commis-
sioners, likely to be publicly available online with one
module dedicated to findings from this trial.
Trial status
This trial is currently recruiting. Recruitment started in
November 2016 (first enrolment 6 December 2016) and
is due to continue through 2018.
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